AI is pulling huge amounts of capital into data centres and specialised computing, and that surge in demand is rippling into healthcare research that depends on complex modelling. British biotechnology stocks sit right in the crosshairs of that shift, with lab science and computing power increasingly tied together. This article highlights three UK listed biotech stocks from our quality focused screener that could deserve a closer look now.
The three British biotechnology stocks below are only a sample from a wider pool, and the full screen surfaced 4 more companies with equally compelling stories that are not covered here. To identify and analyze those extra biotech opportunities with similar balance sheet strength and value traits, head straight into the Biotech Stocks screener.
Overview: Bioventix develops and supplies sheep monoclonal antibodies and test kits used in diagnostic assays for thyroid, vitamin D, cardiac and oncology testing.
Operations: The group generated about £13 million from biotechnology activities, with roughly £11 million coming from customers outside the UK and European Union.
Market Cap: £102 million
Bioventix plugs directly into the Biotech Stocks screener theme through its diagnostic antibodies, pairing biotech risk with established profitability. Earnings sit on a 58.7% net margin and a 66.7% ROE, while the P/E of 13.4x undercuts both peer and sector averages. That combination of strong economics and low headline valuation only holds together if one unseen pressure stays contained.
If you want to see whether that pressure point is already priced in, go straight to the 2 key rewards and 1 important major warning sign for the full picture hiding behind Bioventix’s margins.
Overview: Oxford Biomedica provides viral vector development and manufacturing for gene and cell therapies, anchored by its LentiVector and AAV platform technologies.
Operations: Oxford Biomedica generates most of its £175 million revenue from manufacturing services at £88 million and development work at £60 million, primarily from United States clients.
Market Cap: £588 million
Oxford Biomedica brings the biotech screener theme to life because its viral vector platforms sit directly behind high risk, high payoff gene therapies. The bearish analyst Narrative on Simply Wall St focuses squarely on how that opportunity interacts with the cost of running a multi site manufacturing network.
“While contracted orders and revenue backlog have risen into the mid hundreds of millions of pounds, the earlier operating EBITDA loss of £7.8 million and the impairment at the France site indicate that if program timing issues reappear when late stage projects transition to commercial supply, the fixed cost base could keep EBITDA margins below current expectations.”
Leave a comment